ClinicalTrials.gg
TerminatedNCT04578548Updated Aug 22, 2024Results posted

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 2 interventional study of GLPG2737 and Placebo in Autosomal Dominant Polycystic Kidney Disease, sponsored by Galapagos NV. Terminated at 20 sites in 7 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was early terminated due to lack of efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy — 5 open to participants now, 9 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Italy.

Enrollment
16th of 18
66 · median 128
Started
2020
with 1 other
Phase 2
4 of 29
1 open now
Registered
17th of 29
by date
Lead sponsor
1 of 29
Galapagos NV

Among the 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 17th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

5 of the 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Polycystic Kidney, Autosomal Dominant with a site in Italy, or all of them as a file.
02

Study summary

This is an exploratory, randomized, double-blind, placebo-controlled, parallel group, multicenter, proof of concept study (Phase 2a), evaluating orally administered GLPG2737 for a double-blind (DB) treatment period of 52 weeks and 4 weeks of follow up as well as an open-label extension (OLE) treatment period of 52 weeks and 4 weeks of follow-up, in participants with rapidly progressing ADPKD.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria for the double-blind period of the study:

  • Documented diagnosis of typical ADPKD, using the Ravine criteria (Ravine, et al., 1994).
  • Rapidly progressive disease, defined as presence of all of the following:

    • Total Kidney Volume (TKV) >750 mL, as determined on imaging not older than 5 years before screening. If historical imaging is not available or older than 5 years, imaging can be performed during the screening period according to local clinical practice (that is, echography, magnetic resonance imaging [MRI])
    • Mayo ADPKD Classification Classes 1C to 1E.
  • at screening between 30 to 90 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) for participants aged 18 to 40 years (inclusive), and between 30 to 60 mL/min/1.73 m\^2 for participants aged 40 to 50 years.
  • Blood pressure ≤ 150/90 millimeters of mercury (mmHg). In case a participant is treated for hypertension, she/he should be on a stable treatment regimen of antihypertensive therapy for at least 8 weeks prior to the screening visit, and during the screening period.

Key Inclusion Criteria for the OLE period of the study:

  • Male and female participants who completed the 52-week double-blind treatment period on product (IP).
  • Participant, according to the investigator's judgment, may benefit from long-term treatment with GLPG2737.

Key Exclusion Criteria for the double-blind period of the study:

  • Congenital absence of 1 kidney, or participant had a previous nephrectomy or has a transplanted kidney or a transplantation is planned in the foreseeable future.
  • Administration of polycystic kidney disease-modifying agents (for example, tolvaptan, somatostatin analogues) or interventions (such as cyst aspiration or cyst fenestration) within 12 weeks prior to the screening visit and during the screening period. In case tolvaptan is not being administered, this should be because of e.g. non-availability, intolerance, or physician's clinical judgment.
  • Any condition or circumstances that, in the opinion of the investigator, may make a participant unlikely or unable to complete the study or comply with study procedures and requirements (for example, unable to undergo magnetic resonance imaging (MRI) due to participant's weight exceeds the weight capacity of the MRI, ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, etc.).

Key exclusion criteria for the OLE period of the study:

  • abnormalities detected on 12-lead (ECG) of either rhythm or conduction, >450 ms, or long QT syndrome.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    GLPG2737 During DB + During OLE

    Participants received 150 milligrams (mg) GLPG2737 capsules orally once daily for 52 weeks in the double-blind (DB) treatment period. Eligible participants were rolled over to an open-label extension (OLE) period to receive 150 mg GLPG2737 orally once daily for 52 weeks.

    Drug: GLPG2737

  • Placebo comparator
    Placebo During DB + GLPG2737 During OLE

    Participants received placebo matched to GLPG2737 capsules orally once daily for 52 weeks in the DB treatment period. Eligible participants were rolled over to an OLE period to receive 150 mg GLPG2737 orally once daily for 52 weeks.

    Drug: GLPG2737 · Drug: Placebo

Interventions

  • Capsules administered orally

  • DrugPlacebo

    Matching placebo capsules administered orally

06

What researchers measure

Primary outcomes

  1. DB Period: Mean Percent Change From MRI Baseline in htTKV

    htTKV is used in participants with ADPKD disease to predict the onset of renal insufficiency. htTKV was calculated using TKV (in mL) obtained from MRI divided by height (in m). MRI Baseline: For MRI assessments, all non-missing values before the first study drug administration in the study +14 days (included) was considered as the primary baseline definition. Results were derived by mean of the individual slopes (i.e. using all MRI performed between baseline and Week 52).

    Time frame: MRI Baseline up to Week 52

  2. DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug, whether or not considered related to it. A serious adverse event (SAE) is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results a congenital anomaly/birth defect or other medically important event. A TEAE was defined as an AE observed after starting administration of the study drug until 30 days after last DB dose or 1 day before OLE dose, whichever occurred first.

    Time frame: From first dose to Week 56

Secondary outcomes

  1. DB Period: Mean Change From Baseline in eGFR

    The eGFR is a test that measures level of kidney function and determines the stage of kidney disease. eGFR was based on CKD-EPI formula (2009) calculated from serum creatinine concentrations. Results were derived by mean of the individual slopes (i.e. using data between baseline and Week 52).

    Time frame: Baseline up to Week 52

  2. DB Period: Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of GLPG2737 and Its Metabolite

    AUC0-tau described the area under the curve limited to the end of a dosing interval. The metabolite of GLPG2737 is M4.

    Time frame: Predose (within 30 minutes prior to dosing), 1, 1.5, 2, 3, 4, 5, 6, 7 hours post dose through Week 52

  3. DB Period: Maximum Observed Plasma Concentration (Cmax) of GLPG2737 and Its Metabolite

    Cmax is the maximum observed plasma concentration of the drug. The metabolite of GLPG2737 is M4.

    Time frame: Predose (within 30 minutes prior to dosing), 1, 1.5, 2, 3, 4, 5, 6, 7 hours post dose through Week 52

07

Results

Posted Aug 22, 2024
Limitations and caveats
The early termination was decided due to the lack of efficacy of GLPG2737, making the expected benefit-risk balance negative.

Participant flow

Participants with autosomal dominant polycystic kidney disease (ADPKD) were enrolled. The study was conducted at 20 sites in 7 countries i.e. Belgium, Czech Republic, Germany, Italy, Netherlands, Poland, and Spain. Out of these 20 activated sites, 3 sites did not enroll any participants. 89 participants were screened, out of which 66 were randomized.

Double-blind Treatment Period (52 Weeks)
Participant flow — Double-blind Treatment Period (52 Weeks)
MilestoneGLPG2737 During DB + During OLEPlacebo During DB + GLPG2737 During OLE
Started4422
Completed4120
Not completed32
Withdrew: Lost to follow-up11
Withdrew: Non compliance with study drug11
Withdrew: Withdrawal by subject10
Open-Label Treatment Period (52 Weeks)
Participant flow — Open-Label Treatment Period (52 Weeks)
MilestoneGLPG2737 During DB + During OLEPlacebo During DB + GLPG2737 During OLE
Started3920
Completed34
Not completed3616
Withdrew: Adverse event11
Withdrew: Withdrawal by subject10
Withdrew: Study terminated by sponsor3415

Outcome measures

PrimaryDB Period: Mean Percent Change From MRI Baseline in htTKV

htTKV is used in participants with ADPKD disease to predict the onset of renal insufficiency. htTKV was calculated using TKV (in mL) obtained from MRI divided by height (in m). MRI Baseline: For MRI assessments, all non-missing values before the first study drug administration in the study +14 days (included) was considered as the primary baseline definition. Results were derived by mean of the individual slopes (i.e. using all MRI performed between baseline and Week 52).

Time frame:
MRI Baseline up to Week 52
Reported as:
Geometric mean · percent change
DB Period: Mean Percent Change From MRI Baseline in htTKV
percent changeGLPG2737 During DBPlacebo During DB
DB Period: Mean Percent Change From MRI Baseline in htTKV8.18 (6.04 to 10.36)9.17 (6.05 to 12.38)
Statistical analysis
  • GLPG2737 During DB vs Placebo During DB · Random coefficient regression model · p = 0.606 · Geometric mean difference: -0.91 · 95% CI -4.34 to 2.64
PrimaryDB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug, whether or not considered related to it. A serious adverse event (SAE) is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results a congenital anomaly/birth defect or other medically important event. A TEAE was defined as an AE observed after starting administration of the study drug until 30 days after last DB dose or 1 day before OLE dose, whichever occurred first.

Time frame:
From first dose to Week 56
Reported as:
Number · participants
DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
participantsGLPG2737 During DBPlacebo During DB
TEAEs4422
Serious TEAEs13
SecondaryDB Period: Mean Change From Baseline in eGFR

The eGFR is a test that measures level of kidney function and determines the stage of kidney disease. eGFR was based on CKD-EPI formula (2009) calculated from serum creatinine concentrations. Results were derived by mean of the individual slopes (i.e. using data between baseline and Week 52).

Time frame:
Baseline up to Week 52
Reported as:
Least squares mean · mL/min/1.73 m^2
DB Period: Mean Change From Baseline in eGFR
mL/min/1.73 m^2GLPG2737 During DBPlacebo During DB
DB Period: Mean Change From Baseline in eGFR-5.44 (-7.34 to -3.54)-3.13 (-5.87 to -0.39)
Statistical analysis
  • GLPG2737 During DB vs Placebo During DB · Random coefficient regression model · p = 0.171 · Least-squares mean difference: -2.31 · 95% CI -5.64 to 1.02
SecondaryDB Period: Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of GLPG2737 and Its Metabolite

AUC0-tau described the area under the curve limited to the end of a dosing interval. The metabolite of GLPG2737 is M4.

Time frame:
Predose (within 30 minutes prior to dosing), 1, 1.5, 2, 3, 4, 5, 6, 7 hours post dose through Week 52
Reported as:
Geometric mean · nanogram* hour per milliliter (ng*h/mL)
DB Period: Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of GLPG2737 and Its Metabolite
nanogram* hour per milliliter (ng*h/mL)GLPG2737 During DB
GLPG273718500 (17500 to 19500)
Metabolite M418700 (17400 to 20200)
SecondaryDB Period: Maximum Observed Plasma Concentration (Cmax) of GLPG2737 and Its Metabolite

Cmax is the maximum observed plasma concentration of the drug. The metabolite of GLPG2737 is M4.

Time frame:
Predose (within 30 minutes prior to dosing), 1, 1.5, 2, 3, 4, 5, 6, 7 hours post dose through Week 52
Reported as:
Geometric mean · ng/mL
DB Period: Maximum Observed Plasma Concentration (Cmax) of GLPG2737 and Its Metabolite
ng/mLGLPG2737 During DB
GLPG27371160 (1110 to 1220)
Metabolite M4873 (813 to 939)

Adverse events

Collected over DB Period: From first dose to Week 56 OLE Period: From first dose to Week 56. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GLPG2737 During DB + During OLE0/44 (0%)3/44 (6.8%)44/44 (100%)
Placebo During DB0/22 (0%)3/22 (13.6%)22/22 (100%)
Placebo During DB + GLPG2737 During OLE0/20 (0%)2/20 (10%)15/20 (75%)
Most frequent serious events
Most frequent serious events
EventGLPG2737 During DB + During OLEPlacebo During DBPlacebo During DB + GLPG2737 During OLE
Cyst ruptureGeneral disorders0/440/221/20
Renal cystRenal and urinary disorders0/440/221/20
Renal abscessInfections and infestations0/441/220/20
Ventricular extrasystolesCardiac disorders0/441/220/20
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/441/220/20
Hypertensive emergencyVascular disorders0/441/220/20
Hepatic cyst infectionInfections and infestations1/440/220/20
Renal cyst infectionInfections and infestations1/440/220/20
DiarrhoeaGastrointestinal disorders1/440/220/20
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/440/220/20
Most frequent other events
Showing 10 of 186
Most frequent other events
EventGLPG2737 During DB + During OLEPlacebo During DBPlacebo During DB + GLPG2737 During OLE
COVID-19Infections and infestations21/445/221/20
HeadacheNervous system disorders11/448/220/20
HypertensionVascular disorders13/444/220/20
Renal painRenal and urinary disorders8/446/222/20
Dry mouthGastrointestinal disorders11/441/221/20
Upper respiratory tract infectionInfections and infestations5/443/225/20
NasopharyngitisInfections and infestations10/445/222/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/442/221/20
Back painMusculoskeletal and connective tissue disorders8/444/220/20
InfluenzaInfections and infestations8/442/221/20

Baseline characteristics

Safety Analysis Set (SAS): All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)GLPG2737 During DBPlacebo During DBTotal
Mean40.6 ± 6.339.6 ± 6.240.3 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)GLPG2737 During DBPlacebo During DBTotal
Female24832
Male201434
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GLPG2737 During DBPlacebo During DBTotal
Hispanic or Latino9211
Not Hispanic or Latino352055
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GLPG2737 During DBPlacebo During DBTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White442266
More than one race000
Unknown or Not Reported000
Height-Adjusted Total Kidney Volume(htTKV)
Height-Adjusted Total Kidney Volume(htTKV)(mL/m)GLPG2737 During DBPlacebo During DBTotal
Mean1069.18 ± 438.061439.23 ± 737.671190.51 ± 575.26
Estimated Glomerular filtration rate (GFR)
Estimated Glomerular filtration rate (GFR)(mL/min/1.73 m^2)GLPG2737 During DBPlacebo During DBTotal
Mean55.5 ± 16.351.6 ± 15.654.2 ± 16.1
08

Study locations

20 sites
  • Cliniques Universitaires St. Luc (UCL)
    Brussels, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, 656 91, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha, 128 08, Czechia
  • Uniklinikum Dresden
    Dresden, 01307, Germany
  • IRCSS Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80131, Italy
  • Uni Campania L. Vanvitelli
    Napoli, 80131, Italy
  • Fondazione Salvatore Maugeri IRCCS
    Pavia, 27100, Italy
  • Amsterdam UMC
    Amsterdam, 1105, Netherlands
  • UMCG
    Groningen, 9713, Netherlands
  • Radboud UMC
    Nijmegen, 6525, Netherlands
  • Specjalistyczne Centrum Medyczne SCM Spółka z o.o.
    Kraków, 31-559, Poland
  • DaVita Sp. z o.o. Stacja Dializ
    Warsaw, 02-758, Poland
  • Szpital Kliniczny UM w Lodzi
    Łódź, 92-213, Poland
  • Fundacion Puigvert
    Barcelona, 08025, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Nefrologia Clinica C.P.
    Madrid, 28041, Spain
  • Hospital Universitario Dr. Peset
    Valencia, 46017, Spain
09

References and documents

Publications

  • Ron T. Gansevoort et al., 2022. The MANGROVE Phase 2 Trial: Study Design and Baseline Characteristics of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD). Abstract (385) presented at the Annual Congress of the American Society of Nephrology, 3-Nov-2022 to 6-Nov-2022.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2022, 25 months.

Results were first posted in Aug 2024, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 8, 2020
StartActual
Nov 10, 2020
Primary completionActual
Dec 14, 2022
CompletionActual
Apr 4, 2023
Results first posted
Aug 22, 2024
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04578548
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Nov 10, 2020
Primary completion
Dec 14, 2022
Completion
Apr 4, 2023
Results posted
Aug 22, 2024
Last update
Aug 22, 2024

Study contacts

Galapagos Study Director
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG-2737

Start the discussion